Compare ELOG & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | CURX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 14.5M |
| IPO Year | N/A | 2025 |
| Metric | ELOG | CURX |
|---|---|---|
| Price | $0.99 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.8K | ★ 193.5K |
| Earning Date | 05-12-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.26 |
| 52 Week High | $3.07 | $9.18 |
| Indicator | ELOG | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 53.90 |
| Support Level | $0.86 | $0.38 |
| Resistance Level | $1.19 | $0.53 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 56.44 | 47.07 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.